2 days Ago By ABMN Staff
American Century Companies Inc. boosted its position in NeoGenomics, Inc. ( NASDAQ:NEO – Free Report ) by 5.
4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,261,756 shares of the medical research company’s stock after purchasing an additional 167,145 shares during the period. American Century Companies Inc.
owned approximately 2.55% of NeoGenomics worth $45,241,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company.
Texas Permanent School Fund Corp increased its holdings in shares of NeoGenomics by 12.7% in the second quarter. Texas Permanent School Fund Corp now owns 125,705 shares of the medical research company’s stock valued at $1,742,000 after buying an additional 14,148 shares in the last quarter.
Candriam S.C.A.
increased its stake in NeoGenomics by 29.9% in the 2nd quarter. Candriam S.
C.A. now owns 487,026 shares of the medical research company’s stock worth $6,755,000 after purchasing an additional 112,009 shares in the last quarter.
Arizona State Retirement System raised its holdings in NeoGenomics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock worth $496,000 after buying an additional 708 shares during the period.
TD Asset Management Inc lifted its stake in NeoGenomics by 3.2% during the second quarter. TD Asset Management Inc now owns 203,646 shares of the medical research company’s stock valued at $2,825,000 after buying an additional 6,400 shares in the last quarter.
Finally, Banque Cantonale Vaudoise boosted its holdings in shares of NeoGenomics by 10.2% in the second quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock worth $244,000 after buying an additional 1,633 shares during the period.
98.50% of the stock is owned by institutional investors. NeoGenomics Stock Performance NASDAQ:NEO opened at $16.
33 on Tuesday. The firm’s 50-day moving average is $15.87 and its 200-day moving average is $14.
93. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -24.
74 and a beta of 1.19. The company has a debt-to-equity ratio of 0.
37, a quick ratio of 1.93 and a current ratio of 2.01.
NeoGenomics, Inc. has a 52-week low of $11.03 and a 52-week high of $21.
22. Analyst Ratings Changes Several research analysts recently weighed in on the company. Stephens reissued an “overweight” rating and set a $19.
00 price target on shares of NeoGenomics in a research report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th.
Finally, Benchmark reiterated a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock.
Based on data from MarketBeat, NeoGenomics currently has a consensus rating of “Moderate Buy” and an average price target of $19.89. Get Our Latest Report on NEO NeoGenomics Profile ( Free Report ) NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. Read More Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for NeoGenomics, Inc. ( NASDAQ:NEO – Free Report ). Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.
com's FREE daily email newsletter ..
